Completed

Open Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

What is being tested

Data Collection

Who is eligible

Generalized Anxiety Disorder+9

+ Anxiety Disorders

+ Mental Disorders

Over 18 Years

+8 Eligibility Criteria

See all eligibility criteria

How is it accessible

Completed

Available upon a request by a licensed MD

Expanded Access

See protocol details

Summary

Principal SponsorEli Lilly and Company

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

The primary objective of this study is to provide duloxetine to investigators for the treatment of patients who have previously participated in neuroscience duloxetine clinical trials and for whom effective alternative therapy is not available.

Official TitleOpen Label Duloxetine Compassionate Use in Patients Who Have Completed a Previous Neuroscience Duloxetine Clinical Trial

NCT00071708

Principal SponsorEli Lilly and Company

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

Over 18 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Generalized Anxiety DisorderAnxiety DisordersMental DisordersDepressive Disorder, MajorDepressive DisorderFibromyalgiaMuscular DiseasesMusculoskeletal DiseasesNervous System DiseasesNeuromuscular DiseasesRheumatic DiseasesMood Disorders

Criteria

3 inclusion criteria required to participate

Male and Female outpatients at least 18 years of age who have previously participated in a Lilly sponsored neuroscience duloxetine clinical trial

All females must have a negative urine pregnancy test at visit 1. Females of childbearing potential must agree to utilize medically acceptable and reliable means of birth control.

Must sign the informed consent document

5 exclusion criteria prevent from participating

Have received treatment within the last 30 days with a drug except for duloxetine that has not received regulatory approval for any indication at the time of study entry

In the opinion of the investigator, patient judged to be at serious suicidal risk.

Serious or unstable hepatic or renal function or unstable narrow angle glaucoma.

Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days prior to visit 1 or potential to use a MAOI during the study or within 5 days of discontinuation of study drug.

Show More Criteria

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 13 locations

Suspended

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Paddington, AustraliaOpen For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. in Google Maps

Suspended

Everton Park, Australia

Suspended

Maroochydore, Australia

Suspended

Southport, Australia

Completed13 Study Centers